Smaller intracranial volume in prodromal Huntington's disease: Evidence for abnormal neurodevelopment

Brain

Volumn 134, Issue 1, 2011, Pages 137-142

  Nopoulos, Peggy C ^a   Aylward, Elizabeth H ^b   Ross, Christopher A ^c   Mills, James A ^a   Langbehn, Douglas R ^a   Johnson, Hans J ^a   Magnotta, Vincent A ^a   Pierson, Ronald K ^a   Beglinger, Leigh J ^a   Nance, Martha A ^d   Barker, Roger A ^e   Paulsen, Jane S ^a  

^a UNIVERSITY OF IOWA   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

brain; brain imaging; brain volumes

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN GROWTH; BRAIN SCINTISCANNING; BRAIN SIZE; CALVARIA; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; BRAIN; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; TRINUCLEOTIDE REPEATS;

EID: 78650699846     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq280     Document Type: Article

References (45)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: APA 1994.
2. Berrios GE, Wagle AC, Markova IS, Wagle SA, Ho LW, Rubinsztein DC, et al. Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. Psychiatry Res 2001; 102: 217-25.
3. Bhide PG, Day M, Sapp E, Schwarz C, Sheth A, Kim J, et al. Expression of normal and mutant huntingtin in the developing brain. J Neurosci 1996; 16: 5523-35.
4. Bode FJ, Stephan M, Suhling H, Pabst R, Straub RH, Raber KA, et al. Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet 2008; 17: 2595-609.
5. Bradley WG Jr, Kortman KE, Burgoyne B. Flowing cerebrospinal fluid in normal and hydrocephalic states: appearance on MR images. Radiology 1986; 159: 611-16.
6. Brown H, Prescott R. Applied mixed models in medicine. New York: Wiley; 1999.
7. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 2001; 24: 182-8.
8. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919-30.
9. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996; 29: 162-73.
10. Dorner JL, Miller BR, Barton SJ, Brock TJ, Rebec GV. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease. Behav Brain Res 2007; 178: 90-7.
11. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Psychiatric symptoms in Huntington's disease before diagnosis: the Predict-HD study. Biol Psychiatry 2007; 62: 1341-6.
12. Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry 1999; 66: 52-6.
13. Giedd JN. Structural magnetic resonance imaging of the adolescent brain. Ann N Y Acad Sci 2004; 1021: 77-85.
14. Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA, et al. Quantitative neuropathological changes in presymp-tomatic Huntington's disease. Ann Neurol 2001; 49: 29-34.
15. Harris G, Andreasen NC, Cizadlo T, Bailey JM, Bockholt HJ, Magnotta VA, et al. Improving tissue segmentation in MRI: a three-dimensional multispectral discriminant analysis method with automated training class selection. J Comput Assist Tomogr 1999; 23: 144-54.
16. Hinton SC, Paulsen JS, Hoffmann RG, Reynolds NC, Zimbelman JL, Rao SM. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc 2007; 13: 539-43.
17. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999; 23: 181-92.
18. Kirkwood SC, Siemers E, Bond C, Conneally PM, Christian JC, Foroud T. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch Neurol 2000; 57: 1040-4.
19. Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 397-408.
20. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation-a longitudinal follow-up study. J Neurol 2004; 251: 935-42.
21. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000; 9: 1259-71.
22. Magnotta V, Harris G, Andreasen NC, O'Leary DS, Yuh WT, Heckel D. Structural MR image processing using the BRAINS2 toolbox. Comput Med Imaging Graph 2002; 26: 251-64.
23. Magnotta VA, Bockholt HJ, Johnson HJ, Christensen GE, Andreasen NC. Subcortical, cerebellar, and magnetic resonance based consistent brain image registration. Neuroimage 2003; 19: 233-45.
24. McCarthy MM. Estradiol and the developing brain. Physiol Rev 2008; 88: 91-124.
25. Mehler MF, Gokhan S. Mechanisms underlying neural cell death in neu-rodegenerative diseases: alterations of a developmentally-mediated cellular rheostat. Trends Neurosci 2000; 23: 599-605.
26. Molero AE, Gokhan S, Gonzalez S, Feig JL, Alexandre LC, Mehler MF. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc Natl Acad Sci USA 2009; 106: 21900-5.
27. Morriss-Kay GM, Wilkie AO. Growth of the normal skull vault and its alteration in craniosynostosis: insights from human genetics and experimental studies. J Anat 2005; 207: 637-53.
28. Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, et al. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol 1991; 50: 729-42.
29. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in het-erozygotes. Cell 1995; 81: 811-23.
30. Nopoulos P, Flaum M, Andreasen NC. Sex differences in brain morphology in schizophrenia. Am J Psychiatry 1997; 154: 1648-54.
31. Nopoulos P, Flaum M, O'Leary D, Andreasen NC. Sexual dimorphism in the human brain: evaluation of tissue volume, tissue composition and surface anatomy using magnetic resonance imaging. Psychiat Res-Neuroim 2000; 98: 1-13.
32. Nopoulos P, Magnotta VA, Mikos A, Paulson H, Andreasen NC, Paulsen JS. Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry 2007; 164: 1428-34.
33. Orr AL, Huang S, Roberts MA, Reed JC, Li S, Li XJ. Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease trans-genic mice. J Biol Chem 2008; 283: 16027-36.
34. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006; 59: 57-63.
35. Paulsen JS, Nopoulos P, Aylward E, Ross C, Johnson H, Magnotta V, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010; 82: 201-7.
36. Pengas G, Pereira JM, Williams GB, Nestor PJ. Comparative reliability of total intracranial volume estimation methods and the influence of atrophy in a longitudinal semantic dementia cohort. J Neuroimaging 2009; 19: 37-46.
37. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000; 20: 3705-13.
38. Roos RA, Vegter-van der Vlis M, Hermans J, Elshove HM, Moll AC, van de Kamp JJ, et al. Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. J Med Genet 1991; 28: 515-9.
39. SAS Institute. SAS/STAT user's guide. Cary, NC 2003.
40. Serra HG, Duvick L, Zu T, Carlson K, Stevens S, Jorgensen N, et al. RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell 2006; 127: 697-708.
41. Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007; 45: 1767-76.
42. Styner M, Brechbuhler C, Szekely G, Gerig G. Parametric estimate of intensity inhomogeneities applied to MRI. IEEE Trans Med Imaging 2000; 19: 153-65.
43. Waddington JL, Buckley PF. The neurodevelopmental basis of schizophrenia. Heidelberg, Germany: Springer-Verlag; 1996.
44. White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 1997; 17: 404-10.
45. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995; 11: 155-63.